ScholarIQanswers from OpenAlex
Novavax (United States)
InstitutionResearch output, impact & collaborations
Novavax (United States) is a institution indexed in ScholarIQ from OpenAlex.
What is known about Novavax (United States)?
ScholarIQrecord summary
Novavax (United States) is a research organisation in Gaithersburg, US. OpenAlex records 412 works and 94,792 citations for it. 227 researchers list it as their most recent affiliation.
How many works does Novavax (United States) have?
ScholarIQindexed works
Novavax (United States) has 412 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Novavax (United States) have?
ScholarIQcitation count
Novavax (United States) has 94,792 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at Novavax (United States)?
ScholarIQresearcher count
Novavax (United States) has 227 researchers in the ScholarIQ index.
What is the average h-index at Novavax (United States)?
ScholarIQavg h-index
Novavax (United States) has an average h-index of 50.5 in OpenAlex.
What is the ROR of Novavax (United States)?
ScholarIQror
The ROR for Novavax (United States) is on the source record.
What is the OpenAlex record for Novavax (United States)?
ScholarIQopenalex
The OpenAlex for Novavax (United States) is on the source record.
Who are the most-cited researchers behind Novavax (United States)?
ScholarIQtop researchers by citations
What are the most-cited papers on Novavax (United States)?
ScholarIQmost cited works
Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine
Cheryl Keech, Gary Albert, Iksung Cho, Andreana Robertson, Patricia Reed, Susan Neal, Joyce S. Plested, Mingzhu Zhu, Shane Cloney-Clark, Haixia Zhou, Gale Smith, Nita Patel, Matthew B. Frieman, Robert Haupt, James Logue, Marisa E. McGrath, Stuart Weston, Pedro A. Piedra, Chinar Desai, Kathleen Callahan, Maggie Lewis, Patricia Price-Abbott, Neil Formica, Vivek Shinde, Louis Fries, Jason D. Lickliter, Paul Griffin, Bethanie Wilkinson, Gregory M. Glenn
Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965.
Bryce D. Smith, Rebecca L. Morgan, Geoff A. Beckett, Yngve Falck–Ytter, Deborah Holtzman, Chong‐Gee Teo, Amy Jewett, Brittney Baack, David B. Rein, Nita Patel, Miriam J. Alter, Anthony Yartel, John W. Ward
SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice
Jing-Hui Tian, Nita Patel, Robert Haupt, Haixia Zhou, Stuart Weston, Holly Hammond, James Logue, Alyse D. Portnoff, James A. Norton, Mimi Guebre‐Xabier, Bin Zhou, Kelsey Jacobson, Sonia Maciejewski, Rafia Khatoon, Malgorzata Wisniewska, Will Moffitt, Stefanie Kluepfel-Stahl, Betty Ekechukwu, James F. Papin, Sarathi Boddapati, C. Jason Wong, Pedro A. Piedra, Matthew B. Frieman, Michael J. Massare, Louis Fries, Karin Lövgren Bengtsson, Linda Stertman, Larry Ellingsworth, Gregory M. Glenn, Gale Smith
Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate
Sandhya Bangaru, Gabriel Ozorowski, Hannah L. Turner, Aleksandar Antanasijevic, Deli Huang, Xiaoning Wang, Jonathan L. Torres, Jolene K. Diedrich, Jing-Hui Tian, Alyse D. Portnoff, Nita Patel, Michael J. Massare, John R. Yates, David Nemazee, James C. Paulson, Greg Glenn, Gale Smith, Andrew B. Ward
Development of Motavizumab, an Ultra-potent Antibody for the Prevention of Respiratory Syncytial Virus Infection in the Upper and Lower Respiratory Tract
Herren Wu, David S. Pfarr, Syd Johnson, Yambasu A. Brewah, Robert M. Woods, Nita Patel, Wendy I. White, James F. Young, Peter A. Kiener
How much of the research on Novavax (United States) is open access?
ScholarIQopen access share
45%OPEN ACCESS